PH-sensitive nanoparticles for colonic delivery of curcumin in inflammatory bowel disease

International Journal of Pharmaceutics

Volumn 473, Issue 1-2, 2014, Pages 203-212

  Beloqui, Ana ^a   Coco, Régis ^a   Memvanga, Patrick B ^a,b   Ucakar, Bernard ^a   Des Rieux, Anne ^a   Préat, Véronique ^a  

^a UNIVERSITÉ CATHOLIQUE DE LOUVAIN   (Belgium)

^b UNIVERSITY OF KINSHASA   (Congo)

Author keywords

Curcumin; Inflammatory bowel disease; Nanoparticles; pH sensitive; PLGA

Indexed keywords

CURCUMIN; EUDRAGIT; NANOPARTICLE; POLYGLACTIN; TUMOR NECROSIS FACTOR ALPHA; ANTIINFLAMMATORY AGENT; DEXTRAN SULFATE; DRUG CARRIER; LACTIC ACID; METHYLMETHACRYLATE-METHACRYLIC ACID COPOLYMER; POLYGLYCOLIC ACID; POLYLACTIC ACID-POLYGLYCOLIC ACID COPOLYMER; POLYMETHACRYLIC ACID DERIVATIVE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELL MEMBRANE PERMEABILITY; CELL VIABILITY; CONTROLLED STUDY; CYTOKINE RELEASE; CYTOTOXICITY; DISEASE SEVERITY; DRUG DELIVERY SYSTEM; DRUG DETERMINATION; DRUG EFFICACY; DRUG FORMULATION; EXPERIMENTAL COLITIS; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MACROPHAGE; MOUSE; NANOENCAPSULATION; NEUTROPHIL CHEMOTAXIS; NONHUMAN; PARTICLE SIZE; PH; PRIORITY JOURNAL; PROTEIN EXPRESSION; WEIGHT REDUCTION; ANIMAL; C57BL MOUSE; CACO 2 CELL LINE; CELL LINE; CHEMICALLY INDUCED; CHEMISTRY; COLITIS; COLON; DISEASE MODEL; DRUG EFFECTS; INFLAMMATORY BOWEL DISEASES; METABOLISM; NEUTROPHIL; PATHOLOGY;

ANIMALS; ANTI-INFLAMMATORY AGENTS; CACO-2 CELLS; CELL LINE; COLITIS; COLON; CURCUMIN; DEXTRAN SULFATE; DISEASE MODELS, ANIMAL; DRUG CARRIERS; FEMALE; HUMANS; HYDROGEN-ION CONCENTRATION; INFLAMMATORY BOWEL DISEASES; LACTIC ACID; MACROPHAGES; MICE, INBRED C57BL; NANOPARTICLES; NEUTROPHILS; POLYGLYCOLIC ACID; POLYMETHACRYLIC ACIDS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84904578762     PISSN: 03785173     EISSN: 18733476     Source Type: Journal    
DOI: 10.1016/j.ijpharm.2014.07.009     Document Type: Article

References (47)

1. B.B. Aggarwal, and K.B. Harikumar Potential therapeutic effects of curcumin, the anti-inflammatory agent, against neurodegenerative, cardiovascular, pulmonary, metabolic, autoimmune and neoplastic diseases Int. J. Biochem. Cell. Biol. 41 2009 40 59
2. M. Alhouayek, D.M. Lambert, N.M. Delzenne, P.D. Cani, and G.G. Muccioli Increasing endogenous 2-arachidonoylglycerol levels counteracts colitis and related systemic inflammation FASEB J. 25 2011 2711 2721
3. H.M. Arafa, R.A. Hemeida, A.I. El-Bahrawy, and F.M. Hamada Prophylactic role of curcumin in dextran sulfate sodium (DSS)-induced ulcerative colitis murine model Food Chem. Toxicol. 47 2009 1311 1317
4. A. Beloqui, R. Coco, M. Alhouayek, M. Solinís, A. Rodríguez-Gascón, G.G. Muccioli, and V. Préat Budesonide-loaded nanostructured lipid carriers reduce inflammation in murine DSS-induced colitis Int. J. Pharm. 454 2013 775 783
5. A. Beloqui, M. Solinís, A.R. Gascón, A. del Pozo-Rodríguez, A. des Rieux, and V. Préat Mechanism of transport of saquinavir-loaded nanostructured lipid carriers across the intestinal barrier J. Control. Release 166 2013 115 123
6. K.K. Chereddy, R. Coco, P.B. Memvanga, B. Ucakar, A. des Rieux, G. Vandermeulen, and V. Préat Combined effect of PLGA and curcumin on wound healing activity J. Control. Release 171 2013 208 215
7. R. Coco, L. Plapied, V. Pourcelle, C. Jerome, D.J. Brayden, Y.J. Schneider, and V. Preat Drug delivery to inflamed colon by nanoparticles: comparison of different strategies Int. J. Pharm. 440 2013 3 12
8. E.M. Collnot, H. Ali, and C.M. Lehr Nano- and microparticulate drug carriers for targeting of the inflamed intestinal mucosa J. Control. Release 161 2012 235 246
9. J. Cui, B. Yu, Y. Zhao, W. Zhu, H. Li, H. Lou, and G. Zhai Enhancement of oral absorption of curcumin by self-microemulsifying drug delivery systems Int. J. Pharm. 371 2009 148 155
10. A. des Rieux, E.G. Ragnarsson, E. Gullberg, V. Preat, Y.J. Schneider, and P. Artursson Transport of nanoparticles across an in vitro model of the human intestinal follicle associated epithelium Eur. J. Pharm. Sci. 25 2005 455 465 (Pubitemid 40853873)
11. A.H. El-Kamel, M.S. Sokar, S.S. Al Gamal, and V.F. Naggar Preparation and evaluation of ketoprofen floating oral delivery system Int. J. Pharm. 220 2001 13 21 (Pubitemid 32476837)
12. J. Epstein, I.R. Sanderson, and T.T. Macdonald Curcumin as a therapeutic agent: the evidence from in vitro, animal and human studies Br. J. Nutr. 103 2010 1545 1557
13. C.A. Fernandes, L. Fievez, A.M. Neyrinck, N.M. Delzenne, F. Bureau, and R. Vanbever Sirtuin inhibition attenuates the production of inflammatory cytokines in lipopolysaccharide-stimulated macrophages Biochem. Biophys. Res. Commun. 420 2012 857 861
14. A. Goel, A.B. Kunnumakkara, and B.B. Aggarwal Curcumin as "Curecumin": from kitchen to clinic Biochem. Pharmacol. 75 2008 787 809
15. F. Grimpen, and P. Pavli Advances in the management of inflammatory bowel disease Intern. Med. J. 40 2010 258 264
16. R. Holma, P. Salmenpera, A. Riutta, I. Virtanen, R. Korpela, and H. Vapaatalo Acute effects of the cys-leukotriene-1 receptor antagonist, montelukast, on experimental colitis in rats Eur. J. Pharmacol. 429 2001 309 318 (Pubitemid 33044006)
17. T.T. Jubeh, Y. Barenholz, and A. Rubinstein Differential adhesion of normal and inflamed rat colonic mucosa by charged liposomes Pharm. Res. 21 2004 447 453 (Pubitemid 38338980)
18. B. Khor, A. Gardet, and R.J. Xavier Genetics and pathogenesis of inflammatory bowel disease Nature 474 2011 307 317
19. H. Kitamura, M. Ito, T. Yuasa, C. Kikuguchi, A. Hijikata, M. Takayama, Y. Kimura, R. Yokoyama, T. Kaji, and O. Ohara Genome-wide identification and characterization of transcripts translationally regulated by bacterial lipopolysaccharide in macrophage-like J774.1 cells Physiol. Genomics 33 2008 121 132 (Pubitemid 351451379)
20. J.E. Krawisz, P. Sharon, and W.F. Stenson Quantitative assay for acute intestinal inflammation based on myeloperoxidase activity. Assessment of inflammation in rat and hamster models Gastroenterology 87 1984 1344 1350 (Pubitemid 15201434)
21. G. Krishna, K. Chen, C. Lin, and A.A. Nomeir Permeability of lipophilic compounds in drug discovery using in-vitro human absorption model, Caco-2 Int. J. Pharm. 222 2001 77 89 (Pubitemid 32525789)
22. A. Kunwar, A. Barik, R. Pandey, and K.I. Priyadarsini Transport of liposomal and albumin loaded curcumin to living cells: an absorption and fluorescence spectroscopic study Biochim. Biophys. Acta 2006 1513 1520 (Pubitemid 44428033)
23. A. Lamprecht, U. Schafer, and C.M. Lehr Size-dependent bioadhesion of micro- and nanoparticulate carriers to the inflamed colonic mucosa Pharm. Res. 18 2001 788 793 (Pubitemid 32783514)
24. Laroui, H., Dalmasso, G., Nguyen, H.T., Yan Y., Sitaraman, S.V., Merlin, D., 2010. Drug-loaded nanoparticles targeted to the colon with polysaccharide hydrogel reduce colitis in a mouse model. Gastroenterology, 138, 843-853, (e841-842).
25. H. Laroui, S.V. Sitaraman, and D. Merlin Gastrointestinal delivery of anti-inflammatory nanoparticles Methods Enzymol. 509 2012 101 125
26. H. Laroui, D.S. Wilson, G. Dalmasso, K. Salaita, N. Murthy, S.V. Sitaraman, and D. Merlin Nanomedicine in GI Am. J. Physiol. Gastrointest. Liver Physiol. 300 2011 G371 G383
27. C. Lautenschläger, C. Schmidt, D. Fischer, and A. Stallmach Drug delivery strategies in the therapy of inflammatory bowel disease Adv. Drug Deliv. Rev. 71 2014 58 76
28. M.H. Leung, and T.W. Kee Effective stabilization of curcumin by association to plasma proteins: human serum albumin and fibrinogen Langmuir 25 2009 5773 5777
29. A. Makhlof, Y. Tozuka, and H. Takeuchi pH-sensitive nanospheres for colon-specific drug delivery in experimentally induced colitis rat model Eur. J. Pharm. Biopharm. 72 2009 1 8
30. Y. Meissner, Y. Pellequer, and A. Lamprecht Nanoparticles in inflammatory bowel disease: particle targeting versus pH-sensitive delivery Int. J. Pharm. 316 2006 138 143 (Pubitemid 43765696)
31. S. Melgar, A. Karlsson, and E. Michaelsson Acute colitis induced by dextran sulfate sodium progresses to chronicity in C57BL/6 but not in BALB/c mice: correlation between symptoms and inflammation Am. J. Physiol. Gastrointest. Liver Physiol. 288 2005 G1328 G1338
32. P.B. Memvanga, R. Coco, and V. Préat An oral malaria therapy: curcumin-loaded lipid-based drug delivery systems combined with é-arteether J. Control. Release 172 2013 904 913
33. P.B. Memvanga, P. Eloy, E.M. Gaigneaux, and V. Preat In vitro lipolysis and intestinal transport of β-arteether-loaded lipid-based drug delivery systems Pharm. Res. 30 2013 2694 2705
34. P.B. Memvanga, J.K. Mbinze, E. Rozet, P. Hubert, V. Préat, and R.D. Marini Development of a liquid chromatographic method for the simultaneous quantification of curcumin, é-arteether, tetrahydrocurcumin and dihydroartemisinin. Application to lipid-based formulations J. Pharm. Biomed. Anal. 88 2014 447 456
35. P.B. Memvanga, and V. Preat Formulation design and in vivo antimalarial evaluation of lipid-based drug delivery systems for oral delivery of β-arteether Eur. J. Pharm. Biopharm. 82 2012 112 119
36. J.L. Mendoza, and M.T. Abreu Biological markers in inflammatory bowel disease: practical consideration for clinicians Gastroenterol. Clin. Biol. 33 Suppl. 3 2009 S158 S173
37. M. Rescigno, G. Rotta, B. Valzasina, and P. Ricciardi-Castagnoli Dendritic cells shuttle microbes across gut epithelial monolayers Immunobiology 204 2001 572 581 (Pubitemid 34134169)
38. G. Rogler Gastrointestinal and liver adverse effects of drugs used for treating IBD Best Pract. Res. Clin. Gastroenterol. 24 2010 157 165
39. C. Schmidt, C. Lautenschlaeger, E.-M. Collnot, M. Schumann, C. Bojarski, J.-D. Schulzke, C.-M. Lehr, and A. Stallmach Nano- and microscaled particles for drug targeting to inflamed intestinal mucosa - a first in vivo study in human patients J. Control. Release 165 2013 139 145
40. A. Stallmach, S. Hagel, and T. Bruns Adverse effects of biologics used for treating IBD Best Pract. Res. Clin. Gastroenterol. 24 2010 167 182
41. K. Sugimoto, H. Hanai, K. Tozawa, T. Aoshi, M. Uchijima, T. Nagata, and Y. Koide Curcumin prevents and ameliorates trinitrobenzene sulfonic acid-induced colitis in mice Gastroenterology 123 2002 1912 1922 (Pubitemid 35408315)
42. F. Talaei, F. Atyabi, M. Azhdarzadeh, R. Dinarvand, and A. Saadatzadeh Overcoming therapeutic obstacles in inflammatory bowel diseases: a comprehensive review on novel drug delivery strategies Eur. J. Pharm. Sci. 49 2013 712 722
43. W. Ulbrich, and A. Lamprecht Targeted drug-delivery approaches by nanoparticulate carriers in the therapy of inflammatory diseases J. R. Soc. Interface 7 Suppl. 1 2010 S55 S66
44. B. Wahlang, Y.B. Pawar, and A.K. Bansal Identification of permeability-related hurdles in oral delivery of curcumin using the Caco-2 cell model Eur. J. Pharm. Biopharm. 77 2011 275 282
45. S. Wirtz, and M.F. Neurath Mouse models of inflammatory bowel disease Adv. Drug Deliv. Rev. 59 2007 1073 1083 (Pubitemid 47615208)
46. Y. Yan, V. Kolachala, G. Dalmasso, H. Nguyen, H. Laroui, S.V. Sitaraman, and D. Merlin Temporal and spatial analysis of clinical and molecular parameters in dextran sodium sulfate induced colitis PLoS One 4 2009 e6073
47. Y.X. Yang, and G.R. Lichtenstein Corticosteroids in Crohn's disease Am. J. Gastroenterol. 97 2002 803 823 (Pubitemid 34408233)